Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Gemina Laboratories Ltd. (C:GLAB)

Business Focus: Laboratory Diagnostic & Testing Substances

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for GLAB within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 21, 2024 09:00 ET
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
VANCOUVER, BC / ACCESSWIRE / March 21, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to provide a strategic update and outlook for 2024 and beyond. The Company is beginning to see results from its 2023 focus on developing large scale commercial partnerships. Our emphasis on developing multiple revenue streams, including product development, licenses, and services, will improve our revenue visibility in the second half of this year. 2024 will see Gemina complete the buildout of ou
Read full article
Mar 19, 2024 08:30 ET
Gemina Announces Closing of $910,000 Convertible Note Financing
VANCOUVER, BC / ACCESSWIRE / March 19, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of $910,000 under its non-brokered private placement (the "Private Placement") of unsecured convertible notes of the Company (the "Notes"). Please see the Company's news release dated February 22, 2024 for additional details regarding the terms o
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
--
3.46
Price to Book - most recent quarter
--
--
2.02
Price to Cash Flow per share - TTM
--
--
9.70
Price to Free Cash Flow per share - TTM
--
--
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 2024577-2,017
Feb 29, 20242,5940
Jan 31, 20242,5001,600
See Short Report

Business Summary

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution

Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. It operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.

See business summary

 

Twitter

Search (past week) for $GLAB.CA

  • No tweets found